EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy is preferred in patients with locally advanced or metastatic NSCLC because of its high specificity, curative effect, and favorable safety profile.